169 related articles for article (PubMed ID: 28054376)
21. Clusterin expression correlates with stage and presence of large cells in mycosis fungoides.
Chandra P; Plaza JA; Zuo Z; Diwan AH; Koeppen H; Duvic M; Medeiros LJ; Prieto VG
Am J Clin Pathol; 2009 Apr; 131(4):511-5. PubMed ID: 19289586
[TBL] [Abstract][Full Text] [Related]
22. Mycosis fungoides with epidermal mucinosis: a variant of mycosis fungoides with a spongiosis-like pattern.
Hu SW; Ratech H; Naeem R; Latkowski JA; Kamino H
J Cutan Pathol; 2015 Oct; 42(10):730-8. PubMed ID: 26009972
[TBL] [Abstract][Full Text] [Related]
23. Mapping Toll-like receptor activity in different stages of cutaneous T-cell lymphoma.
Kado JA; Shango M; Mehregan C; Mehregan DR
Am J Dermatopathol; 2012 Oct; 34(7):691-8. PubMed ID: 22407070
[TBL] [Abstract][Full Text] [Related]
24. miR-155 is involved in tumor progression of mycosis fungoides.
Moyal L; Barzilai A; Gorovitz B; Hirshberg A; Amariglio N; Jacob-Hirsch J; Maron L; Feinmesser M; Hodak E
Exp Dermatol; 2013 Jun; 22(6):431-3. PubMed ID: 23711069
[TBL] [Abstract][Full Text] [Related]
25. Expression of human beta-defensins in patients with mycosis fungoides.
Gambichler T; Skrygan M; Appelhans C; Tomi NS; Reinacher-Schick A; Altmeyer P; Kreuter A
Arch Dermatol Res; 2007 Jul; 299(4):221-4. PubMed ID: 17415576
[TBL] [Abstract][Full Text] [Related]
26. Mycosis fungoides with spongiosis: A potential diagnostic pitfall.
Shamim H; Johnson EF; Gibson LE; Comfere N
J Cutan Pathol; 2019 Sep; 46(9):645-652. PubMed ID: 30989664
[TBL] [Abstract][Full Text] [Related]
27. Tumor Stage Mycosis Fungoides in a Child.
Dulmage BO; Villaseñor-Park J; Ho J; Geskin LJ; Grandinetti LM
Pediatr Dermatol; 2015; 32(4):e156-8. PubMed ID: 25892093
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of hypoxia-inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides--cutaneous T-cell lymphoma: clinical implications.
Alcántara-Hernández M; Torres-Zárate C; Pérez-Montesinos G; Jurado-Santacruz F; Domínguez-Gómez MA; Peniche-Castellanos A; Ferat-Osorio E; Neri N; Nambo MJ; Alvarado-Cabrero I; Moreno-Lafont M; Huerta-Yepez S; Bonifaz LC
Int J Cancer; 2014 May; 134(9):2136-45. PubMed ID: 24127318
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
31. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical staining for CD45R isoforms in paraffin sections to diagnose mycosis fungoides-type cutaneous T-cell lymphoma.
Ismail SA; Han R; Sanborn SL; Stevens SR; Cooper KD; Wood GS; Gilliam AC
J Am Acad Dermatol; 2007 Apr; 56(4):635-42. PubMed ID: 17367612
[TBL] [Abstract][Full Text] [Related]
33. Hypopigmented mycosis fungoides: case reports and literature review.
Qari MS; Li N; Demierre MF
J Cutan Med Surg; 2000 Jul; 4(3):142-8. PubMed ID: 11003719
[TBL] [Abstract][Full Text] [Related]
34. Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides.
Benner MF; Ballabio E; van Kester MS; Saunders NJ; Vermeer MH; Willemze R; Lawrie CH; Tensen CP
Exp Dermatol; 2012 Aug; 21(8):632-4. PubMed ID: 22776000
[TBL] [Abstract][Full Text] [Related]
35. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease.
Vermeer MH; Geelen FA; Kummer JA; Meijer CJ; Willemze R
Am J Pathol; 1999 Apr; 154(4):1203-10. PubMed ID: 10233858
[TBL] [Abstract][Full Text] [Related]
36. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
37. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis.
Smith BD; Wilson LD
Oncology (Williston Park); 2003 Sep; 17(9):1281-8. PubMed ID: 14569854
[TBL] [Abstract][Full Text] [Related]
38. Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets.
Seif El Nasr H; Shaker OG; Fawzi MM; El-Hanafi G
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):103-8. PubMed ID: 22151832
[TBL] [Abstract][Full Text] [Related]
39. ALK Expression is a Rare Finding in Mycosis Fungoides.
Covington M; Cassarino D; Abdulla F
Am J Dermatopathol; 2017 May; 39(5):342-343. PubMed ID: 28426485
[TBL] [Abstract][Full Text] [Related]
40. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA.
Asadullah K; Döcke WD; Haeussler A; Sterry W; Volk HD
J Invest Dermatol; 1996 Dec; 107(6):833-7. PubMed ID: 8941670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
